Matt Wilson's startup story begins with a shortage, but not the sort investors put in a market-sizing slide. It was a shortage of hours. As an emergency doctor and anaesthetist, he watched clinicians spend entire shifts keeping up with immediate care. Some emergency shifts, he later recalled, stretched 14 hours without time to eat. Asking the same team to identify research candidates, manage outreach and shepherd a study through its paperwork was less an invitation than a practical joke.
There was another limit he could not ignore. During his years as a doctor with the Royal Marines, Wilson found it frustrating to help only one patient at a time. Clinical work mattered precisely because it was personal, but research offered a different unit of impact. A study could change what happened for thousands of people the clinician would never meet. The trouble was that the people closest to patients usually had no capacity left to run it.
“I had a limited ability to affect change.”Matt Wilson, on leaving the one-to-one limit of clinical work
A business plan in the cold
The setting for Wilson's entrepreneurial turn was northern Norway, during a Royal Marines training camp. In one six-week stretch of military downtime, he skipped the television and wrote the plan for uMed 1.0. A magazine profile of Box co-founder Aaron Levie supplied some useful provocation. Levie appeared self-effacing and intensely driven, proof to Wilson that a founder did not have to arrive in the standard costume of entrepreneurial certainty.
The first premise was to make research accessible to everyday doctors. Wilson posted the plan on an investor network, met early backers and began collecting advice. Then reality performed its essential service: the idea was worthy, but the model was not scalable. Wilson abandoned the mechanism without abandoning the problem. The contacts, criticisms and practical lessons from that false start became raw material for the company that followed.
Stay stubborn about the problem and editable about the solution. A failed model can still leave behind a useful network, better questions and evidence about where the friction really lives.
He is suspicious of tidy creation myths. Ideas, in his telling, germinate over time. They sharpen as experience adds structure, until commitment looks less like a lightning strike and more like the next honest step. uMed emerged from that accumulation: medical training, frontline frustration, military stretches of forced patience and one early business that taught him what not to build.
The quiet machine behind the study
Founded in 2018, uMed was designed to put research work closer to routine care while keeping provider oversight and patient consent intact. Its platform connects with a provider's electronic records to identify potentially suitable participants. Once a provider approves a programme, outreach and remote consent can be managed through the system. Information collected from the patient, the record and, when needed, the clinician can then be joined into a study dataset.
The important piece is not merely finding a record that fits a search. Wilson argues that useful research requires a compliant route back to the patient. Consent makes it possible to validate what is already in the record, ask new questions and collect additional information from home. The cohort can become a continuing research relationship rather than a frozen database extract.
That difference changes the tempo of a study. Traditional recruitment often begins from zero, with staff searching charts and contacting people one project at a time. A reusable cohort preserves the connection, so later questions can begin with participants who have already chosen to hear about research. The software does not erase the human decision. It arranges the process so that consent, communication and follow-up are part of the design from the start.
This architecture also reveals uMed's business instinct. Healthcare providers hold the trusted relationship and the records, yet lack spare staff. Researchers have questions and budgets, yet struggle to find suitable, representative participants quickly. uMed sits between them, trying to reduce the administrative tax on the first group and the recruitment delay for the second.
Trust before traction
There is a reason the numbers took time. Wilson was asking healthcare organizations to let a young company work near sensitive records and communicate about research under their name. The technical sale was inseparable from institutional trust. uMed had to show that providers retained control, that patient choice was meaningful and that the company would resist the swagger that has made many care organizations wary of technology vendors.
Wilson has called the signing of uMed's first GP federation his proudest early achievement. It was the moment an organization without a prior case study agreed to take a serious chance on the model. Venture funding might look better in a headline, but the first provider supplied a more valuable asset: permission to prove the system in the environment where it had to work.
The company raised £3.7 million in 2020, then announced a £9.8 million Series A in July 2023 from Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital. By that second round, it reported more than 450 UK GP practices representing five million patients and more than 6,000 participants recruited into studies. The capital was intended in part to widen the company's North American reach. Wilson's own base is now Greater Boston, placing him near one of the densest life-sciences networks in the United States.
The founder with the pink hammock problem
The work has not been solemn every minute. At an early speed-pitching event, Wilson arrived with a deep healthcare business and discovered that the room leaned heavily toward consumer products. The entrepreneur ahead of him carried a giant bright-pink inflatable hammock. Wilson remembers looking at it and wondering how much easier his life might be if he were selling hammocks.
The joke lands because the temptation is real. A hammock can be touched, understood and possibly purchased before the elevator doors reopen. Research infrastructure has to cross clinical workflow, software integration, procurement, governance and patient communication before anyone gets to enjoy it. Its elegance appears as work that does not have to happen.
“We need to hire people and we need to make decisions.”Matt Wilson, speaking in 2025 about the work of scaling uMed
Wilson's operating advice is equally unvarnished. He warns founders not to take résumés at face value. A founding team needs compatible values, equal work ethic and personalities that survive pressure, not just complementary keywords. As uMed expanded, that became a preference for people able to act independently and solve problems without waiting for a perfectly drawn map.
His approach to investors is compact: under-promise and over-deliver. His approach to instinct is more nuanced. Gut feeling, he suggests, is experience compressed by the brain into a signal. It deserves attention, followed by an attempt to disprove it. Advice belongs in the same category. Listen carefully, but examine the incentives and judgment of the person giving it. A founder who follows every opinion will eventually walk in a circle.
From episodes to a network
Wilson's ambition has remained consistent even as uMed's products have matured. He wants research participation to become possible for far more providers and patients, and he wants the resulting network to make high-quality evidence accessible beyond major pharmaceutical companies. In practice, that has meant building reusable, consented cohorts and enabling continued engagement rather than treating every study as an isolated episode.
Recent public conversations show him concentrating on the operating details behind that ambition. In 2025 he discussed hiring, relationship-led business development in the United States, deal quality and ambassador programmes. In 2026 he wrote about the imbalance between sponsors and research sites, and appeared at an industry event to argue for lower barriers to evidence generation. The subject has widened, but the original missing-hours problem is still visible beneath it.
That continuity may be the clearest fact about Wilson. Medicine taught him where the bottleneck hurt. Military life gave him an odd pocket of time to sketch an answer. The failed first version removed the romance. The first provider supplied trust. Funding supplied reach. What remains is the long, decidedly unglamorous work of making a complicated process feel ordinary.
Some founders sell the future as spectacle. Wilson's preferred future looks more like plumbing: present, dependable and largely unnoticed until it fails. If uMed works as intended, a busy clinician does not become a part-time research administrator. A suitable patient hears about an opportunity through a trusted provider. A researcher gets a cohort that can answer the question. And nobody has to pretend there was an extra hour in the day.